United Therapeutics (UTHR) Tops Q1 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
United Therapeutics (UTHR) PT Bumped to $203 at Wedbush Despite Top-Line Miss
April 28, 2015 12:24 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and lifted her price target on United Therapeutics Corp. (NASDAQ: UTHR) from $198 to $203 despite Q1 results which missed on the top line.
"Despite the revenue miss, Q1 net sales for Remodulin of $146.3MM beat consensus... More
